Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko, Eisai to Copromote Partner’s Generics from October
May 16, 2018
- Eisai Poised to Focus on Maximization of Lenvima Value: CEO
May 16, 2018
- Eisai Chalks Up 1st Double-Digit Growth in 11 Years on Merck Deal, Global Brands
May 16, 2018
- Taisho to Launch Voluntary Redundancy Program
May 15, 2018
- Velcade Sales Would Slide 50%, but Weber Stresses Takeda’s Strong Momentum
May 15, 2018
- Taisho and Fujifilm to Dissolve Capital Alliance and Transform Their JV Companies to Wholly Owned Subsidiaries
May 15, 2018
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
- Lilly, Sapporo Medical Univ. Ink Antigen Research Deal for Colorectal Cancer Immunotherapy
May 14, 2018
- Santen Plans Add’l Trial on Uveitis Treatment DE-109 after FDA Rebuff
May 14, 2018
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Towa Wins Top Court Victory over Elplat Patent
May 14, 2018
- Kyorin Holdings Aims to Boost New Drug Sales to Over 50% of Overall Sales by FY2019: Pres.
May 14, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
- Astellas Gets Rights to Urology Drug Rosiptor in Asia-Pacific Region
May 11, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- YL Biologics Files Enbrel Biosimilar in Japan
May 11, 2018
- MSD Japan Seeks Adjuvant Melanoma Nod for Keytruda
May 11, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Shire Buyout a Must for Takeda’s Leap in Global Arena: Board Chair
May 10, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…